Genicular Artery Embolization for Osteoarthritis
(SHAM-PAIN Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called Genicular Artery Embolization (GAE) to determine its effectiveness in reducing knee pain caused by osteoarthritis, a common joint condition. Participants will receive either the GAE procedure or a sham treatment (a fake version with no active treatment) to compare the effects. The study seeks individuals who have experienced knee pain from osteoarthritis for more than six months and have not found relief with other treatments. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it mentions that patients should not have had a corticosteroid injection in the affected knee within 3 months before joining the trial and should not be using long-acting corticosteroids within 6 months (or short-acting within 3 months).
What prior data suggests that Genicular Artery Embolization is safe for reducing pain in knee osteoarthritis?
Research has shown that Genicular Artery Embolization (GAE) is generally a safe procedure for treating knee osteoarthritis. Studies have found that the most common side effect is temporary changes in skin color. Some patients reported a tingling sensation, like pins and needles, though this was less common.
In terms of effectiveness, about 78% to 92% of patients experienced significant pain relief, with their pain reduced by at least half. These findings suggest that while GAE can have some mild side effects, most patients tolerate it well.12345Why are researchers excited about this trial's treatment for osteoarthritis?
Researchers are excited about Genicular Artery Embolization (GAE) for osteoarthritis because it targets the blood vessels that contribute to inflammation and pain directly. Unlike standard treatments such as pain relievers, physical therapy, or injections, which manage symptoms, GAE addresses the root cause by reducing blood flow to the affected area using a temporary embolic agent. This technique, specifically using the Lipiojoint method, offers the potential for quick relief without lasting damage to surrounding tissues. Such an innovative approach might lead to more effective and longer-lasting pain management for osteoarthritis patients.
What evidence suggests that Genicular Artery Embolization might be an effective treatment for knee osteoarthritis?
Research has shown that genicular artery embolization (GAE), which participants in this trial may receive, can help reduce pain for people with knee osteoarthritis. Studies indicate that about 78–92% of patients experienced a significant decrease in pain, with at least a 50% reduction within a year. In some cases, pain relief ranged from 60–80% over six to 24 months. The procedure provided lasting relief for moderate-to-severe knee pain without harming nearby tissues. Overall, GAE presents a promising option for managing knee pain from osteoarthritis.23467
Who Is on the Research Team?
Osman Ahmed, MD
Principal Investigator
University of Chicago Department of Radiology
Are You a Good Fit for This Trial?
This trial is for individuals with severe knee osteoarthritis pain that hasn't improved with regular medical treatments. Participants should be willing to undergo a procedure and follow-up assessments. Specific eligibility details are not provided, so interested individuals should inquire further.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo Genicular Artery Embolization (GAE) or a sham procedure to assess pain reduction in knee osteoarthritis
Follow-up
Participants are monitored for changes in pain and analgesic use at multiple time points post-intervention
What Are the Treatments Tested in This Trial?
Interventions
- Genicular Artery Embolization
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Chicago
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborator